Original ResearchMetformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus
Introduction
The incidence of prostate cancer varies by 25-fold among different countries [1]. In general, developed countries in Europe and North America have a higher incidence than less developed countries in Asia and Africa [1]. In contrast to the decreasing incidence in well-developed countries, the incidence in Asian populations is increasing [1]. In Taiwan, the age-standardised incidence of [2] and mortality from [3] prostate cancer are both increasing in the general population.
Metformin is a commonly used oral antidiabetic drug in patients with type 2 diabetes mellitus (T2DM), and may exert anticancer effects [4]. However, whether metformin can affect the risk of incident prostate cancer is still a matter of debate. While some studies suggested a null association [5], [6], [7], [8], [9], a potential beneficial effect was observed in others [10], [11]. One study even suggested a significantly higher risk for patients having >36 metformin prescriptions [12]. A recent meta-analysis including four studies [2], [6], [12], [13] showed a null association with a pooled hazard ratio of 0.92 (95% confidence interval: 0.73–1.17) [14].
Because the association between metformin and incident prostate cancer is controversial and studies conducted in Asian populations are still sparse, the present study aimed to evaluate whether metformin use could be associated with the risk of incident prostate cancer in Taiwanese male patients with T2DM using the National Health Insurance (NHI) database. A new-user design and a time-dependent approach for metformin use in data analyses were applied in order to minimise the potential confounding factors and biases commonly seen in studies using an administrative database.
Section snippets
Materials and methods
This population-based retrospective cohort study was approved by the ethics review board of the National Health Research Institutes (approval number 99274). The study used the NHI database and included all patients with a diagnosis of diabetes mellitus during the period from 1996 (the earliest database available) to 2009. A detailed description of the NHI database can be seen elsewhere [2], [15]. Diabetes mellitus was coded 250.1–250.9 and prostate cancer, 185, based on the International
Results
Fig. 1 shows the flowchart for the procedures followed in creating the cohort of male patients with new-onset T2DM and aged ⩾40 years at entry during 1998–2002. At first, 411,783 male patients were recruited. After further excluding patients with type 1 diabetes (n = 1232), those with a diagnosis of prostate cancer before diabetes diagnosis (n = 2641), those with a duplicated identification number (n = 39), unclear information on date of birth or sex (n = 7404) and a follow-up duration of <180 days (n =
Discussion
The findings suggested that metformin use in male patients with T2DM was significantly associated with a lower risk of incident prostate cancer, which was dose–responsive, independent of potential confounders and consistent in various sensitivity analyses (Table 2, Table 3, Table 4).
Findings from previous observational studies in humans are conflicting. The population-based case–control (1001 cases and 942 controls) study by Wright and Stanford from the United States of America (USA) showed an
Conflict of interest statement
None declared.
Acknowledgement
The author thanks the National Science Council (NSC102-2314-B-002-067) of Taiwan for continuous support on epidemiological studies on diabetes and arsenic-related health issues.
References (26)
- et al.
Endometrial cancer: a review and current management strategies: Part II
Gynecol Oncol
(2014) - et al.
The influence of antidiabetic medications on the development and progression of prostate cancer
Cancer Epidemiol
(2012) - et al.
The association of diabetes mellitus with liver, colon, lung, and prostate cancer is independent of hypertension, hyperlipidemia, and gout in Taiwanese patients
Metabolism
(2012) - et al.
Global cancer statistics
CA Cancer J Clin
(2011) Diabetes and risk of prostate cancer: a study using the National Health Insurance
Diabetes Care
(2011)Prostate cancer mortality in Taiwanese men: increasing age-standardized trend in general population and increased risk in diabetic men
Ann Med
(2011)- et al.
The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo
Mol Cancer Ther
(2012) - et al.
Metformin use and prostate cancer in Caucasian men: results from a population-based case–control study
Cancer Causes Control
(2009) - et al.
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Diabetologia
(2009) - et al.
Association between metformin use and risk of prostate cancer and its grade
J Natl Cancer Inst
(2013)
Metformin does not affect cancer risk: a cohort study in the U.K. clinical practice research datalink analyzed like an intention-to-treat trial
Diabetes Care
Type 2 diabetes mellitus, glycemic control, and cancer risk
Eur J Cancer Prev
Metformin and the incidence of prostate cancer in patients with type 2 diabetes
Cancer Epidemiol Biomarkers Prev
Cited by (81)
Antidiabetic medications and the risk of prostate cancer in patients with diabetes mellitus: A systematic review and meta-analysis
2022, Pharmacological ResearchCitation Excerpt :After the removal of duplicates, 7695 citations were further excluded based on titles and abstracts, leaving 129 for full-text review. After careful assessment, 46 articles (with 47 independent studies) fulfilled the inclusion criteria and were included in our meta-analysis (13 RCTs, 7 case-control and 27cohort studies) [7,11–13,17,29,32–34,40–76]. The characteristics of the included studies were showed in Table S1.
Metformin and risk of cancer among patients with type 2 diabetes mellitus: A systematic review and meta-analysis
2021, Primary Care DiabetesCitation Excerpt :Despite the length of its use, continuing research on metformin's mechanisms of action and particularly its potential role in cancer has restored its popularity [9]. Recently, the associations of risk relating to cancer with the use of metformin in T2DM patients have already been widely studied [10–76]. However, the results remained inconsistent.
Targeting lipid metabolism in metastatic prostate cancer
2023, Therapeutic Advances in Medical OncologyAssociation of Metformin and Other Diabetes Medication Use and the Development of New-Onset Dry Age-Related Macular Degeneration: A Case–Control Study
2023, Investigative Ophthalmology and Visual ScienceMetformin Reduces the Risk of Hearing Loss: A Retrospective Cohort Study
2023, Otolaryngology - Head and Neck Surgery (United States)The relationship between metformin consumption and cancer risk: An updated umbrella review of systematic reviews and meta-analyses
2023, International Journal of Preventive Medicine